United States securities and exchange commission logo





                            June 7, 2021

       Markus Warmuth
       President and Chief Executive Officer
       Monte Rosa Therapeutics, Inc.
       645 Summer Street, Suite 102
       Boston, MA 02210

                                                        Re: Monte Rosa
Therapeutics, Inc.
                                                            Amendment No. 2 to
Draft Registration Statement on Form S-1
                                                            Submitted May 21,
2021
                                                            CIK No. 0001826457

       Dear Dr. Warmuth:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 2 to Draft Registration Statement on Form S-1 submitted on
May 21, 2021

       Prospectus Summary
       Overview, page 1

   1.                                                   We note your revisions
in response to comment 2. Please further revise your disclosure to
                                                        remove your references
to "highly validated" proteins and similar statements throughout
                                                        your registration
statement that could imply that your product candidates are more likely
                                                        to receive FDA approval
than others.
   2.                                                   We note your revisions
in response to comment 3. You continue to describe your product
                                                        candidates as "potent"
throughout your registration statement and state that they have
                                                        demonstrated the
potential for "potent antitumor activity" on page 105. Please revise
 Markus Warmuth
Monte Rosa Therapeutics, Inc.
June 7, 2021
Page 2
       these and similar statements in your registration statement, as they
continue to
       inappropriately indicate your conclusions regarding the efficacy of your
product
       candidates.
Our Pipeline, page 3

3.     Refer to comment 5. Please include separate columns for Phase 1 and
Phase 2 trials or tell
       us the basis for your belief that you will be able to conduct Phase 1/2
trials for all your
       product candidates.
Capitalization , page 82

4.     Please reconcile the 7,699,359 shares outstanding as of March 31, 2021
disclosed in your
       capitalization table to the 6,079,905 outstanding shares disclosed on
pages F-30 and F-32
       as of March 31, 2021. Please note this comment also applies to your
outstanding shares
       utilized in your calculations for your net tangible and pro forma net
tangible book value
       (deficit) per share as of March 31, 2021 located on page 84.
Business
Collaboration and option agreement, page 136

5.     We note your revised disclosure in response to comment 13. Please
further revise to
       disclose a dollar amount of aggregate future potential milestone
payments to be paid under
       the agreement.
       You may contact Tara Harkins at 202-551-3639 or Lynn Dicker at
202-551-3616 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Kasey Robinson at 202-551-5880 or Jeffrey Gabor at 202-551-2544 with
any other
questions.



                                                            Sincerely,
FirstName LastNameMarkus Warmuth
                                                            Division of
Corporation Finance
Comapany NameMonte Rosa Therapeutics, Inc.
                                                            Office of Life
Sciences
June 7, 2021 Page 2
cc:       Robert E. Puopolo, Esq.
FirstName LastName